Serological profile of John Cunningham virus (JCV) in patients with multiple sclerosis
ABSTRACT Treatment options for multiple sclerosis (MS) have changed over the last few years, bringing about a new category of drugs with more efficient profiles. However, these drugs have come with a whole new profile of potential adverse events that neurologists have to learn well and quickly. One...
Similar Items
-
Safety of switching from natalizumab straight into fingolimod in a group of JCV-positive patients with multiple sclerosis
by: Yara Dadalti Fragoso, et al.
Published: (2016-08-01) -
Natalizumab treatment for multiple sclerosis: updates and considerations for safer treatment in JCV positive patients
by: Luiz Henrique da Silva Nali, et al.
Published: (2014-12-01) -
Systematic review of the published data on the worldwide prevalence of John Cunningham virus in patients with multiple sclerosis and neuromyelitis optica
by: Sonia Patricia Castedo Paz, et al.
Published: (2018-01-01) -
Patients’ satisfaction with and views about treatment with disease-modifying drugs in multiple sclerosis
by: Caroline Vieira Spessotto, et al.
Published: (2016-08-01) -
The Influence of Host Genetics on JCV and EBV Antibody Levels in Multiple Sclerosis Patients and Controls
by: Strid, Elin
Published: (2012)